Table 1.

Characteristics of 15 Patients With Sclerotic-Type Chronic Graft-vs-Host Disease (cGVHD)

Patient No./Sex/Age, y	Primary Diagnosis	Time From Stem Cell Transplantation, moa	cGVHD
			Onset	Other Organ Involvement at the Time of Evaluation
1/F/40	Non-Hodgkin lymphoma	33	Progressive	Ophthalmologic, GI, hepatic, J/F, oral, and vulvovaginal
2/F/39	AML	16	Quiescent	Ophthalmologic, GI, hepatic, J/F, oral, pulmonary, and vulvovaginal
3/M/40	AML	53	Progressive	Ophthalmologic, J/F, oral, and pulmonary
4/F/42	CML	39	De novo	Ophthalmologic, J/F, oral, and pulmonary
5/M/56	MM	37	De novo	J/F and oral
6/M/62	MM	105	Progressive	J/F and oral
7/F/38	AML	29	Progressive	Ophthalmologic, hepatic, J/F, oral, pulmonary, and vulvovaginal
8/M/57	Myelodysplastic syndrome	45	Progressive	Ophthalmologic, J/F, and oral
9/M/51	CML	21	De novo	Hepatic, J/F, and oral
10/M/45	T-cell lymphoblastic leukemia	26	De novo	Ophthalmologic, hepatic, J/F, and oral
11/M/40	AML	67	De novo	Ophthalmologic, J/F, and oral
12/M/32	T-cell lymphoma	22	De novo	GI, hepatic, J/F, and oral
13/M/57	Chronic lymphocytic leukemia	52	Progressive	J/F
14/F/20	Acute lymphoblastic leukemia	26	De novo	Ophthalmologic, GI, hepatic, J/F, oral, and pulmonary
15/M/60	Myeloid metaplasia with myelofibrosis	21	Progressive	Ophthalmologic, hepatic, and oral

Abbreviations: AML, acute myelogenous lymphoma; CML, chronic myelogenous leukemia; GI, gastrointestinal; J/F, joint and fascia (physiatry assessment); MM, multiple myeloma.

^aInterval between stem cell transplantation and evaluation at the National Institutes of Health.